

ODONNELL FRANCIS E JR  
Form 4  
September 14, 2018

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
ODONNELL FRANCIS E JR

2. Issuer Name and Ticker or Trading Symbol  
BIODELIVERY SCIENCES INTERNATIONAL INC [BDSI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
09/12/2018

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O BIODELIVERY SCIENCES INTL, INC., 4131 PARKLAKE AVENUE, SUITE 225

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

RALEIGH, NC 27612

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                                      |
| Common Stock                    | 09/12/2018                           |  | M <sup>(1)</sup>               |   | 133,333   | A  | \$ 0<br>(1)                                |
| Common Stock                    | 09/12/2018                           |  | S <sup>(2)</sup>               |   | 66,667  | D  | \$<br>(3) (9)                              |
| Common Stock                    | 09/13/2018                           |  | A                              |   | 6,806   | A  | \$ 0<br>(4)                                |
| Common Stock                    | 09/13/2018                           |  | M <sup>(5)</sup>               |   | 46,000  | A  | \$ 0<br>(5)                                |

Edgar Filing: O'DONNELL FRANCIS E JR - Form 4

|              |            |  |                         |        |   |                              |         |   |
|--------------|------------|--|-------------------------|--------|---|------------------------------|---------|---|
| Common Stock | 09/13/2018 |  | <u>M</u> <sup>(5)</sup> | 62,500 | A | \$ 0<br><u>(6)</u>           | 569,121 | D |
| Common Stock | 09/13/2018 |  | A                       | 53,438 | A | \$ 0<br><u>(7)</u>           | 622,559 | D |
| Common Stock | 09/13/2018 |  | <u>S</u> <sup>(2)</sup> | 84,372 | D | \$<br>2.84<br><u>(8) (9)</u> | 538,187 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount Number Shares                                    |
| Restricted Stock Units                     | \$ 0   | 09/12/2018                           |  | <u>M</u> <sup>(1)</sup>        | 133,333   | 09/12/2018 09/12/2018                                    | Common Stock 133,333  |
| Restricted Stock Units                     | \$ 0   | 09/13/2018                           |  | <u>A</u> <sup>(4)</sup>        | 6,806   | 09/13/2018 09/13/2018                                    | Common Stock 6,806  |
| Restricted Stock Units                     | \$ 0   | 09/13/2018                           |  | <u>M</u> <sup>(5)</sup>        | 46,000  | 09/13/2018 03/01/2019                                    | Common Stock 46,000   |
| Restricted Stock Units                     | \$ 0   | 09/13/2018                           |  | <u>M</u> <sup>(6)</sup>        | 62,500  | 09/13/2018 02/06/2020                                    | Common Stock 62,500   |
| Restricted Stock Units                     | \$ 0   | 09/13/2018                           |  | <u>A</u> <sup>(7)</sup>        | 53,438  | 09/13/2018 09/13/2018                                    | Common Stock 53,438   |

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

ODONNELL FRANCIS E JR  
C/O BIODELIVERY SCIENCES INTL, INC., X  
4131 PARKLAKE AVENUE, SUITE 225  
RALEIGH, NC 27612

## Signatures

/s/ Francis E.  
O'Donnell Jr. 09/14/2018

\_\_Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares of common stock were acquired by the Reporting Person as a result of the vesting of 133,333 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 23, 2015 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 12, 2018.

(2) The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.

(3) On September 12, 2018, the Reporting Person sold an aggregate of 66,667 shares of the Issuer's Common Stock at a weighted average price of \$2.83 per share. The highest sale price for the Common Stock was \$2.85 per share and the lowest sale price was \$2.80 per share.

(4) The shares of common stock were acquired by the Reporting Person in connection with the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018.

(5) The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest on March 1, 2019.

(6) The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.

(7) The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the Plan subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.

(8) On September 13, 2018, the Reporting Person sold an aggregate of 84,372 shares of the Issuer's Common Stock at a weighted average price of \$2.84 per share. The highest sale price for the Common Stock was \$2.90 per share and the lowest sale price was \$2.90 per share.

(9) The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.